JAHA:QRS片段在成人法洛四联症危险分层中的作用

2018-12-17 xiangting MedSci原创

存在重度QRS-f可用作常规临床指标的补充数据。

即使修复成功,法洛四联症患者(TOF)仍有出现心血管事件的风险。目前的一些风险分层工具需要先进的影像检查和侵入性研究,因此难以应用于常规的患者治疗。最近一项研究表明QRS片段(QRS-f)可以预测TOF患者的死亡率。这项研究旨在通过评估QRS-f的严重程度是否可以预测不同TOF人群的全因死亡率,来验证这一结果。

研究人员回顾了梅奥成人先天性心脏病数据库,查找从1990年到2017年有心电图的TOF患者。QRS-f定义为心电图≥2个相邻导联的QRS波群有凹口,并与束支传导阻滞无关,被分类为无、轻度(≤3个导联)、中度(4个导联)或重度(≥5个导联)。该研究的465名患者中(年龄37±14岁),161名(35%)存在QRS-f:轻度(n=43,9%)、中度(n=77,17%)和重度(n=41,9%)。随访13.6±8.2年期间,55名患者死亡(12%)。在调整其他心电图参数、患者人口学和房室性心律失常后,QRS-f严重程度仍然是全因死亡率的独立预测因子(风险比,每一类1.74; 95%置信区间,1.08-2.93 [P=0.041])。

存在重度QRS-f可用作常规临床指标的补充数据,以确定是否应对非持续性室性心动过速患者进行介入电生理学研究等干预,或对心室容量低于指南阈值的严重肺动脉返流患者进行肺动脉瓣置换。

原始出处:

Alexander C. Egbe. Role of QRS Fragmentation for Risk Stratification in Adults With Tetralogy of Fallot. JAHA. 13 December 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1792931, encodeId=284b1e929318e, content=<a href='/topic/show?id=09c51498630' target=_blank style='color:#2F92EE;'>#QRS片段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14986, encryptionId=09c51498630, topicName=QRS片段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Mon Sep 16 17:20:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720521, encodeId=227e1e2052119, content=<a href='/topic/show?id=09bf36e741d' target=_blank style='color:#2F92EE;'>#危险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36774, encryptionId=09bf36e741d, topicName=危险分层)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5032846700, createdName=tidiq, createdTime=Thu May 16 13:20:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268008, encodeId=286e12680085f, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Dec 19 01:20:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421504, encodeId=cd66142150431, content=<a href='/topic/show?id=068c6486e77' target=_blank style='color:#2F92EE;'>#法洛四联症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64867, encryptionId=068c6486e77, topicName=法洛四联症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f87f3671641, createdName=tongyongming, createdTime=Wed Dec 19 01:20:00 CST 2018, time=2018-12-19, status=1, ipAttribution=)]
    2019-09-16 paperyu
  2. [GetPortalCommentsPageByObjectIdResponse(id=1792931, encodeId=284b1e929318e, content=<a href='/topic/show?id=09c51498630' target=_blank style='color:#2F92EE;'>#QRS片段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14986, encryptionId=09c51498630, topicName=QRS片段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Mon Sep 16 17:20:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720521, encodeId=227e1e2052119, content=<a href='/topic/show?id=09bf36e741d' target=_blank style='color:#2F92EE;'>#危险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36774, encryptionId=09bf36e741d, topicName=危险分层)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5032846700, createdName=tidiq, createdTime=Thu May 16 13:20:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268008, encodeId=286e12680085f, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Dec 19 01:20:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421504, encodeId=cd66142150431, content=<a href='/topic/show?id=068c6486e77' target=_blank style='color:#2F92EE;'>#法洛四联症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64867, encryptionId=068c6486e77, topicName=法洛四联症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f87f3671641, createdName=tongyongming, createdTime=Wed Dec 19 01:20:00 CST 2018, time=2018-12-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1792931, encodeId=284b1e929318e, content=<a href='/topic/show?id=09c51498630' target=_blank style='color:#2F92EE;'>#QRS片段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14986, encryptionId=09c51498630, topicName=QRS片段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Mon Sep 16 17:20:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720521, encodeId=227e1e2052119, content=<a href='/topic/show?id=09bf36e741d' target=_blank style='color:#2F92EE;'>#危险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36774, encryptionId=09bf36e741d, topicName=危险分层)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5032846700, createdName=tidiq, createdTime=Thu May 16 13:20:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268008, encodeId=286e12680085f, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Dec 19 01:20:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421504, encodeId=cd66142150431, content=<a href='/topic/show?id=068c6486e77' target=_blank style='color:#2F92EE;'>#法洛四联症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64867, encryptionId=068c6486e77, topicName=法洛四联症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f87f3671641, createdName=tongyongming, createdTime=Wed Dec 19 01:20:00 CST 2018, time=2018-12-19, status=1, ipAttribution=)]
    2018-12-19 zhaohui6731
  4. [GetPortalCommentsPageByObjectIdResponse(id=1792931, encodeId=284b1e929318e, content=<a href='/topic/show?id=09c51498630' target=_blank style='color:#2F92EE;'>#QRS片段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14986, encryptionId=09c51498630, topicName=QRS片段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Mon Sep 16 17:20:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720521, encodeId=227e1e2052119, content=<a href='/topic/show?id=09bf36e741d' target=_blank style='color:#2F92EE;'>#危险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36774, encryptionId=09bf36e741d, topicName=危险分层)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5032846700, createdName=tidiq, createdTime=Thu May 16 13:20:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268008, encodeId=286e12680085f, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Dec 19 01:20:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421504, encodeId=cd66142150431, content=<a href='/topic/show?id=068c6486e77' target=_blank style='color:#2F92EE;'>#法洛四联症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64867, encryptionId=068c6486e77, topicName=法洛四联症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f87f3671641, createdName=tongyongming, createdTime=Wed Dec 19 01:20:00 CST 2018, time=2018-12-19, status=1, ipAttribution=)]

相关资讯

Heart:成年法洛四联症患者的主动脉疾病及治疗

虽然主动脉瘤常见,但是进行性主动脉扩张并不常见。

Circ: Cardiovascular Interventions:瓣中瓣经导管肺动脉瓣置换患者生物瓣框架的目的性折断

初步经验表明,BPV框架目的性折断有助于瓣中瓣TPVR后达到更大的ID和更好的血液动力学状况。

Heart:婴儿法洛四联症一期修复与手术和经导管矫治的比较

在小婴儿中,与PrR相比, RVOTd与更多的RVOT再介入、更少的PVR、更少的死亡相关,尤其是第一次手术时不足60天的婴儿。

JAHA:法洛四联症修复术后住院时间长短的预测因素

由此可见,Fallot四联症修复术后的住院时间部分由患者和手术因素决定。一些因素(例如,有症状新生儿的手术策略)可能可能有所改变。这些结果可能会影响患者的心理咨询、手术方式的选择以及术后护理。

Circulation:修复的法洛四联症患者肺动脉瓣置换术后死亡和室性心动过速的术前预测因子

这项针对rTOF患者的观察性研究中,PVR时年龄较大、PVR前RV肥大和功能不全可以预测短期内出现术后死亡和持续性VT。

Heart:成人心脏植入式电子设备与法洛四联症

目前的研究提供了有用的结果数据来帮助患者咨询和临床决策。需要进一步研究来探索降低设备发电机更换术后感染风险的方法。